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Abstract
The development of Parkinson’s disease (PD) causes dysfunction of the frontal cortex, which contributes to the hall-
mark motor symptoms and is regarded as one of the primary causes of the affective and cognitive impairments ob-
served in PD. Treatment with L-3,4-dihydroxyphenylalanine (L-DOPA) alleviates motor symptoms but has mixed
efficacy in restoring normal cognitive functions, which is further complicated by the psychoactive effects of the drug.
We investigated how L-DOPA affects gene expression in the frontal cortex in an animal model of unilateral PD. We
performed RNA sequencing (RNA-Seq) analysis of gene expression in the frontal cortex of rats with 6-
hydroxydopamine (6-OHDA)-induced unilateral dopaminergic lesions treated with L-DOPA, for twoweeks. The analysis
of variance identified 48 genes with a significantly altered transcript abundance after L-DOPA treatment. We also per-
formed a weighted gene coexpression network analysis (WGCNA), which resulted in the detection of five modules con-
sisting of genes with similar expression patterns. The analyses led to three primary observations. First, the changes in
gene expression induced by L-DOPA were bilateral, although only one hemisphere was lesioned. Second, the changes
were not restricted to neurons but also appeared to affect immune or endothelial cells. Finally, comparisons with data-
bases of drug-induced gene expression signatures revealed multiple nonspecific effects, indicating that a part of the
observed response is a common pattern activated by multiple types of drugs in different target tissues. Taken together,
our results identify cellular mechanisms in the frontal cortex that are involved in the response to L-DOPA treatment.
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Significance Statement
The development of Parkinson’s disease (PD) causes dysfunction of the frontal cortex, which contributes to the
motor and cognitive impairments observed in PD. L-3,4-dihydroxyphenylalanine (L-DOPA) improves motor
symptoms but has mixed efficacy in restoring normal cognitive functions. We investigated how L-DOPA affects
gene expression in the frontal cortex in an animal model of unilateral PD. We identified 48 genes with L-DOPA-
altered expression levels and gene clusters that follow similar drug-evoked expression patterns. Our findings
suggest that the response to L-DOPA was bilateral, involved distinct cell types and overlapped with expression
changes evoked by drugs of multiple classes in different tissues. Overall, our results identify cellular mechanisms
in the frontal cortex that are involved in the response to L-DOPA treatment.
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Introduction
Parkinson’s disease (PD) is a neurodegenerative disor-
der that leads to a progressive loss of dopaminergic neu-
rons of the substantia nigra in the ventral midbrain
(Hornykiewicz, 1998). The primary symptoms of PD are
motor impairments, including tremors, muscle rigidity,
and slowness of movement. However, the progression of
the disease is also associated with the development of
nonmotor symptoms, including cognitive deficits and af-
fective disorders (Martinez-Martin et al., 2007; Aarsland
et al., 2010; Riedel et al., 2010). The cognitive symptoms
of PD are attributed to impaired function of the frontal
cortex (Sawada et al., 2012; O’Callaghan et al., 2014;
Mihaescu et al., 2019), possibly resulting from depletion
of monoamine neurotransmitters and acetylcholine
(Riekkinen et al., 1998; Mattila et al., 2001; Halliday et al.,
2014; Buddhala et al., 2015) as well as neurodegenera-
tion affecting the cortex in the final stages of the disease
(Braak et al., 2003; González-Redondo et al., 2014;
Armstrong, 2017). The impaired function of the frontal
cortex also contributes to the motor symptoms of PD be-
cause of altered activity and the loss of specificity of ef-
ferent neurons (Rowe et al., 2002; Vercruysse et al.,
2014). The cellular mechanisms associated with impaired
frontal cortex activity remain only partly understood. A
number of studies have assessed changes in the transcrip-
tome and proteome in prefrontal cortex samples derived
postmortem from PD patients, and in some cases, the re-
sults are supplemented with large-scale analysis of single
nucleotide polymorphisms (Duke et al., 2006; Dumitriu et
al., 2012, 2016; Riley et al., 2014; Hoss et al., 2016).
Extensive changes in either transcription or protein abun-
dance were observed, including differences in the expres-
sion of genes encoding metallothioneins, the transcription
factor FOXO1 and its network of regulated genes as well
as mitochondrial genes, proteasome components, and
multiple short RNAs. Nevertheless, the reported results are
not in clear consensus with regard to the underlying mech-
anisms. Additionally, most of the analyses were based on
samples from patients suffering from late stages of the dis-
ease who had received extensive treatment. Thus, it is diffi-
cult to distinguish whether the observed effects should be
attributed to late-stage neurodegeneration, neurotransmit-
ter depletion or the effects of long-termmedication.
The primary treatment of PD relies on L-3,4-dihydroxy-
phenylalanine (L-DOPA), a dopamine precursor. L-DOPA
is effective in alleviating motor impairments, especially in
the initial period of treatment, but displays mixed efficacy
against the nonmotor symptoms of PD. For example,
L-DOPA was observed to improve working memory
(Simioni et al., 2017) and cognitive flexibility but simulta-
neously increased impulsivity (Cools et al., 2003) and
failed to restore impaired sequence learning (Ghilardi et
al., 2007) in PD patients. Moreover, the administration of
L-DOPA altered frontal cortex connectivity in healthy vol-
unteers and had psychoactive effects, increasing impul-
sivity and altering performance in tasks dependent on
executive functions (Kelly et al., 2009; Shiner et al., 2015).
The molecular adaptations involved in the effects of L-
DOPA on the frontal cortex remain elusive.
A model commonly used to study the effects of dopa-
mine depletion on brain physiology involves 6-hydroxy-
dopamine (6-OHDA)-induced lesions of dopaminergic
neurons (Ungerstedt, 1968; Schwarting and Huston,
1996; Simola et al., 2007). Lesioning is typically per-
formed unilaterally, which permits comparison of the
functioning of a dopamine-depleted hemisphere and an
intact hemisphere. In addition, 6-OHDA lesioning is
widely used because it reproduces a PD-like phenotype
resulting from damage to the ventral midbrain neurons
and involves the disruption of mitochondrial activities
that mediate cytotoxic processes (Simola et al., 2007;
Bezard et al., 2013; Kreiner, 2015); thus, 6-OHDA le-
sioning has potential construct validity as a model of
human PD (Hauser and Hastings, 2013). Several studies
have examined the effects of 6-OHDA lesions, in some
cases followed by L-DOPA treatment, on gene expression
in the forebrain and striatum in particular (Berke et al.,
1998; Konradi et al., 2004; Heiman et al., 2014; Smith et al.,
2016). These studies revealed that neurons on the lesioned
side of the striatum exhibited changes in the expression of
immediate early-response genes (IEGs), Grin1 (an essential
NMDA receptor subunit), Stx6 (involved in exocytosis),
or Ldhb (metabolism). To the best of our knowledge, no
studies have comprehensively examined transcriptomic
changes evoked by L-DOPA in the frontal cortex.
Here, we investigated the effects of L-DOPA on gene
expression in the frontal cortex of rats with unilateral 6-
OHDA lesions of the ascending dopaminergic pathways in
the medial forebrain bundle (MFB). We analyzed L-DOPA-
regulated gene expression in the contexts of potential regu-
latory mechanisms, cell-type specificity, and similarities to
the transcriptional signatures of other drugs.
Materials and Methods
Animals
The tissue samples used in this study were prepared as
part of a separate study (Lorenc-Koci E and Kaminska K,
unpublished observations). All animal procedures were
performed in accordance with the European Union guide-
lines for the care and use of laboratory animals (Directive
2010/63/EU) and were approved by the II Local
Institutional Animal Care and Use Committee in Krakow
(permit no. 846/2011). Adult male Wistar Han rats
(Charles River) with an initial body weight of 3006 20 g
were maintained in the institutional animal facility (five ani-
mals per cage) under standard laboratory conditions (22°
C, 12/12 h light/dark cycle, lights on beginning at 7 A.M.).
Animals had unlimited access to food and water. The rats
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were unilaterally lesioned by the infusion of 6-OHDA hy-
drochloride into the left MFB. The animals were anesthe-
tized with a 1:1 v/v mixture of ketamine (50mg/kg,
Biowet) and diazepam (2.5mg/kg, Polfa), administered in
a volume of 1 ml/kg body weight. A stainless steel needle
(0.28-mm outer diameter) was inserted through a hole in
the skull, and its tip was placed in the left MFB at the fol-
lowing coordinates, according to the atlas of Paxinos and
Watson (1986): A/P = 2.8 mm, L = 11.8 mm, D/V = 8.6
mm. 6-OHDA hydrochloride (8mg, free base) was dis-
solved in 4ml sterile 0.9% NaCl with 0.05% ascorbic acid.
The 6-OHDA solution was infused into the MFB through a
10-ml Hamilton syringe at a flow rate of 0.5ml/min, and the
cannula was left in place for another 5min after the infu-
sion stopped. The animals received desipramine hydro-
chloride (25mg/kg, i.p.) 30min before surgery to prevent
noradrenergic neuron damage. After surgery, the rats
were allowed to recuperate for twoweeks, and then the
extent of the lesion was verified using the apomorphine-
induced rotation test. Individual animals were placed in
automated rotameters (Panlab) after the injection of apo-
morphine (0.25mg/kg, s.c.). Following an acclimatization
period of 5min, rats’ movements in both contraversive
(right) and ipsiversive (left) directions were recorded. The
inclusion criterion for additional experiments was 98
contraversive full-body turns in 1 h; however, in the case
of samples used in RNA sequencing (RNA-Seq) analy-
ses, the lowest number of rotations was 121.5 (see
Extended Data Fig. 1-1). On the day following the rota-
tion test, rats started a 14-d treatment period with L-
DOPA (12.5 mg/kg, i.p., once daily) combined with ben-
serazide hydrochloride (6.25mg/kg, i.p., 30min before
L-DOPA). The control animals received a 0.9% (w/v)
NaCl solution. Rats were decapitated 1 h after receiving
the last dose of L-DOPA or saline.
Measurement of striatal dopamine content
Tissue dopamine content was assessed in the striatal
samples separately for the lesioned and nonlesioned
sides by reverse-side high-performance liquid chroma-
tography (HPLC) with coulometric detection. Striatal sam-
ples were dissected on an ice-chilled plate and then
stored at 80°C before being processed. Samples were
homogenized in ice-cold 0.1 M perchloric acid with 0.05
mM ascorbic acid and centrifuged (10,000g, 10min).
The supernatants were filtered through 0.2-mm cellulose
filters (Alltech Associates Inc) and injected into the HPLC
system (P680 pump, ASI-100 autosampler, TCC-100
thermostated column compartment, Dionex) equipped
with a C18 reverse-phase column (150 3 mm i.d.,
3-mm particle size) fitted with a 10 3 mm precolumn
(Thermo Fisher Scientific). Detection was conducted
using a Coulochem III detector (ESA) equipped with a
guard cell (ESA 5020) with the electrode set at 600mV
and a dual electrode analytical cell (ESA 5010). Potentials
were set at 350mV for the first electrode and 220 nV for
the second electrode. Temperatures of the column and the
analytical cell were maintained at 30°C. The mobile phase
consisted of 35 mM citrate/47 mM disodium phosphate
buffer (pH 4.2), supplemented with 0.25 mM
ethylenediaminetetraacetic acid, 0.25 mM sodium octyl sul-
fonate, 2.4%methanol, and 1.3% acetonitrile. The mea-
surement was performed at a maintained flow rate of
0.8 ml/min. Dopamine was quantified by peak area com-
parisons with freshly prepared standards. Chromeleon
Chromatography Data System (Thermo Scientific) v6.8 soft-
ware was used to analyze the collected data.
RNA-Seq
Frontal cortex samples from both hemispheres were
dissected separately on an ice-chilled plate using the ol-
factory bulbs and the most anterior bifurcation of the mid-
dle cerebral artery as orientation points to make cuts in
the frontal plane. Striatal tissue was removed from the
sections, and the cortices were separated into the left
and right sides and stored at 80°C before proceeding.
According to the rat brain atlas (Paxinos and Watson,
1986), the following cortical areas were included in the
samples: primary and secondary motor, prelimbic, infra-
limbic, cingulate, insular, orbital, piriform, dorsal pedun-
cular, and primary somatosensory (A/P: 4.2–2.2 mm).
Tissue samples were homogenized using a TissueLyser
(QIAGEN), and total RNA was extracted with an RNeasy
Mini kit (QIAGEN) using a QIAcube (QIAGEN) in accord-
ance with the manufacturer’s protocol. The integrity
and concentration of the extracted RNA were assessed
using an Agilent RNA 6000 Nano kit on a 2100 Bioanalyzer
(Agilent). Based on RNA integrity number values (RIN. 7.2;
see Extended Data Fig. 1-1), samples from five animals
per group were chosen for RNA-Seq. RNA-Seq was
performed as an external service by Novogene. Briefly,
poly(A) RNA was isolated from the total RNA samples
by the addition of oligo(dT) beads. cDNA libraries were
prepared on a template of randomly fragmented mRNA
using the NEBNext Ultra II Directional RNA Library
Prep kit for Illumina (New England Biolabs). Given that
eight samples out of 20 initially contained,200 ng of
total RNA, all the samples were processed to prepare
cDNA from poly(A) RNA following the low-input proto-
col. Complete cDNA libraries consisting of reads 250–
300 bp in length acquired from the samples were sub-
jected to sequencing on an Illumina system (150 bp,
paired-end, 20 million reads per sample).
Data preprocessing and differential expression
analysis
A quality check of the raw RNA-Seq data were per-
formed with FastQC v0.11.8 in R 3.4. The reads were
aligned to the Rnor6.0 rat reference genome from the
Ensembl database using HISAT2 v2.1.0 (Kim et al., 2019).
Transcript counts were normalized to fragments per kilo-
base of transcript per million fragments mapped (FPKM)
values with the Cufflinks v2.2.1 package (Trapnell et al.,
2010). We used mixed model two-way ANOVA with lesion
as a within-subject factor and treatment as a between-
subject factor on log2(11FPKM) values for each gene to
detect statistically significant differences. The Benjamini–
Hochberg false discovery rate (FDR) correction for multi-
ple comparisons was used to adjust p values. Statistical
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significance testing was performed on transcripts with
mean log2(11FPKM) values .1. The BioMart interface to
the Ensembl database was used for annotation of the
transcripts. Hierarchical clustering was performed using
distances calculated as (1- Pearson’s R2). Genes with
FDR values,0.05 for the L-DOPA treatment effect are re-
ferred to as “differentially expressed” genes. For these
genes, we also analyzed exon expression to differentiate
between different annotated gene transcripts. Mixed
model two-way ANOVA with FDR correction was used to
determine the effects of hemisphere, treatment and their
interaction on transcript isoform abundance. Mean cover-
age (more than two reads per site) of alternative splicing
variants of two of the differentially expressed genes was
plotted using the ggsashimi v0.5.0 package (Garrido-
Martín et al., 2018).
Identification of coexpression networks
Weighted gene coexpression network analysis (WGCNA)
was performed using the WGCNA package v1.68
(Langfelder and Horvath, 2008) in R v3.6.1 and applied
with a step-by-step approach to construct coexpres-
sion networks from genes with mean log2(11FPKM)
values .1. Briefly, a soft-threshold power of 11 was
set based on scale-free topology calculations. Then,
adjacency values were transformed into a topology
overlap matrix (TOM) with TOMtype = “signed,” and
TOM-based dissimilarity (dissTOM) was defined as 1-TOM.
A network dendrogram of genes was constructed based on
average linkage hierarchical clustering and dissTOM with
the “dynamic tree cut” method and the minimum module
size was set to 30. The resulting gene modules were as-
signed arbitrary color names for easier reference, and the
“gray” module comprised of genes that did not match the
inclusion criteria for any other module. Module eigengene
values were clustered based on their correlation, and mod-
ules identified by cutreeDynamic were merged based on the
threshold MEDissThres=0.5 using the mergeCloseModules
function.
Transcription factor binding
The Seqinspector tool was used to assess overrepre-
sentation of transcription factor-binding sites in the pro-
moter regions of differentially expressed genes (Piechota
et al., 2016). Seqinspector uses datasets from ChIP-seq
experiments performed in mouse or human cells; thus,
we translated the list of rat genes to their mouse homo-
logs and used the mm10 mouse genome assembly as
background. Rat genes in the lists were translated to
mouse homologs with biomaRt v2.40.5 (Durinck et al.,
2005). The following rat genes were excluded because
of the existence of more than one or no mouse homo-
logs or differences in the symbols’ names: Il6r and
Nfkbia in the case of the differentially expressed genes,
and Nfkbia, Nat8f3, Gpr52, RGD1311899, Rcor2l1,
Spag5, LOC100912481, and LOC100911313 in the
case of the “salmon” module genes. The resulting re-
cords from corresponding sequencing experiments
(tracks) were considered statistically significant if their
Bonferroni-corrected p, 0.05.
Cell-type specificity of gene expression
Analysis of the brain cell subtypes in which transcripts
of the differentially expressed genes were present was
performed using RNA-Seq Data Navigator from the Cell
Types Database (Allen Institute for Brain Science, 2015).
The database is based on RNA-Seq profiling of mouse
cortical cells, and we used the list of murine homologs of
the rat genes indicated by ANOVA as described above.
Dipk2a, Noct, and Cavin2 mouse genes were not recog-
nized by the database and were excluded from the analy-
sis along with Nfkbia and Il6r. The result of this analysis
was the prevalence of transcripts of our differentially ex-
pressed genes within different cell subtypes (Tasic et al.,
2018). The exported group fraction values for each gene
were then used to plot a heatmap.
Annotation enrichment analysis
The differentially expressed and salmon cluster genes
were analyzed for annotation enrichment using the
enrichR package v2.1, an R interface to the Enrichr web
server (Chen et al., 2013; Kuleshov et al., 2016). Enrichr
uses the human genome as the reference set; thus, we
used biomaRt v2.40.5 to identify human homologs of rat
genes. Genes with different symbols, genes without a
human homolog, and genes that had .1 human homo-
log were excluded from the analysis. The following
genes were excluded: Zfp189 and Nfkbia from the list of
differentially expressed genes and RGD1311899, Zfp189,
Nat8f3, Nfkbia, Gpr52, Sik1, Zfp521, Rcor2l1, Spag5,
LOC100912481, and LOC100911313 from the list of
genes included in the salmon WGCNA module. The re-
sults were considered significant at an adjusted p, 0.05.
Code accessibility




We used RNA-Seq to assess the effects of L-DOPA
treatment on gene expression in the frontal cortex in ani-
mals with dopaminergic lesions. Experiments were per-
formed on samples derived from animals that underwent
induction of unilateral lesions of dopaminergic neurons
with 6-OHDA followed by 14d of L-DOPA treatment. A di-
agram summarizing the procedure is shown in Figure 1A.
The lesions caused .99% loss of dopamine content in
the ipsilateral striatum on the lesioned side, and similar ef-
ficiency was noted in the L-DOPA-treated group (Fig.
1B,C). We dissected the left and right frontal cortices and
separately isolated total RNA from each of them. For both
treatment groups, i.e., saline or L-DOPA, we analyzed five
paired samples (left and right cortices from the same rat,
20 samples in total). RNA-Seq of poly(A)-enriched cDNA
yielded on average 26.4 million pairs of raw reads per
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sample. The sequence reads were mapped to the
Ensembl rat genome assembly Rnor6.0 using HISAT2.
The reads were aligned to a total number of 33,883 se-
quences, and counts were normalized to FPKM values.
There were 12,455 genes with a mean log2(11FPKM)
value .1. These genes included 12,034 protein-coding
genes, 259 pseudogenes, 98 long intergenic noncoding
RNAs, two mitochondrial rRNAs, one nucleolar rRNA, two
ribozymes, three scaRNAs, and one snoRNA. Raw RNA-
Seq data are available at BioProject (https://www.ncbi.
nlm.nih.gov/bioproject/; accession no. PRJNA547879).
To identify differentially expressed genes, we per-
formed mixed model two-way ANOVA with FDR correc-
tion for multiple comparisons. The comparison of the
lesioned versus nonlesioned side was treated as a “with-
in” factor to limit potential effects of differences in the ex-
tent of the lesion between animals. Out of 12,455 genes,
there were 48 genes with FDR values smaller than 0.05 for
the “treatment” factor, as summarized in Figure 2. No
genes were differentially expressed between the lesioned
(left) and nonlesioned (right) frontal cortices, and no statis-
tically significant interactions between effects were ob-
served (Extended Data Fig. 2-1). L-DOPA treatment
caused an increase in the abundance of transcripts corre-
sponding to 38 genes (upper part of the heatmap) and
downregulated 10 genes (lower part). All the differen-
tially expressed genes were protein-coding genes and
had functions related to the immune response (Bcl6,
Ifngr1, and Il6r), modification of the extracellular matrix
(Hyal2 and Mmp9), neuronal signal transduction
(Chrm4), circadian rhythm (Per1), cellular uptake (Tfrc
and Slc2a1), stress response (Sgk1), cell differentiation
(Sox2 and Nedd9), and response to hypoxia (Ddit4).
Moreover, we noted that several genes, including Per1,
Sgk1, Errfi1, Id1, and Klf4, were associated with the im-
mediate early response. Mean transcript abundancies
of the differentially expressed genes normalized as
log2(11FPKM) were in the range of 1.16 (Mmp9) to
6.75 (Tspan17).
For 13 out of 48 differentially expressed genes, alter-
native transcript isoforms were identified, namely,
Dipk2a (2 splicing variants), Grasp (2), Hsd17b12 (2),
Hyal2 (2), Mmp9 (2), Mtmr1 (2), Nedd9 (3), Rnf39 (3),
Sgk1 (4), Slc2a1 (2), Tinagl1 (2), Tspan17 (2), and Zfp189
(2; see Extended Data Fig. 2-2). Mixed model two-way
ANOVA with FDR correction for multiple comparisons re-
vealed two significant results at the transcript level.
L-DOPA altered the transcript abundance of Dipk2a-202,
Grasp-201, Mmp9-201, Nedd9-201, Rnf39-201, Sgk1-201,
Sgk1-204, Slc2a1-201, Tinagl1-201, Tspan17-201, and
Figure 1. A, Treatment scheme of rats with unilateral lesions of dopaminergic neurons as a model of PD. Male adult rats were in-
fused with 8mg/4ml 6-OHDA into their left MFB. The toxin was used to kill dopaminergic neurons to produce an animal model of
PD. Two weeks later, the animals were injected subcutaneously with 0.25mg/kg apomorphine (APO) to induce rotational behavior.
The number of rotations in 1 h was scored, and only the animals that exhibited at least 98 contraversive rotations (as an indication
of sufficient nigral degeneration; for detailed information on number of rotations, see Extended Data Figure 1-1) were used in the fol-
lowing procedures. One day after the APO test, the treatment regime started. Control rats received intraperitoneal saline, whereas
the experimental group received intraperitoneal benserazide (6.25mg/kg) once daily for 14 d followed by L-DOPA (12.5mg/kg). The
animals were decapitated 1 h after the last dose of saline or L-DOPA, and their frontal cortex and striatum tissue was individually
dissected from each hemisphere. B, Dopamine (DA) content in the striatum of saline-treated (C) and L-DOPA-treated animals is pre-
sented as % of the mean of the samples from the right hemisphere.
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Zfp189-201. The Mmp9-201 isoform was also differentially
expressed on the contralateral side (FDR, 0.05 for the
“hemisphere” factor; for details, see Extended Data Fig. 2-
3A). Additionally, two out of four splicing variants of Sgk1
were regulated by L-DOPA in the opposite way. Specifically,
the Sgk1-201 isoform abundance increased after treat-
ment, whereas Sgk1-204 decreased (Extended Data
Fig. 2-3B).
Identification of coexpression networks
To identify networks of coregulated genes, we em-
ployed WGCNA. This method addresses some of the
weaknesses associated with the identification of differen-
tially expressed genes using null hypothesis testing, such
as arbitrary significance criteria or the assumption that the
expression of individual genes is independent. We
performed step-by-step WGCNA with a soft-threshold
power of 11, and the lowest number of the scale-free to-
pology R2 was .0.8. The 12 455 genes were clustered
with the dynamic tree cut method, which resulted in the
detection of 17 modules, each labeled with a color (color
names are arbitrary and only used for easier reference;
Fig. 3A). Five modules were detected at the merging
threshold of 0.5 (Extended Data Fig. 3-1): “brown” with
7148 genes (including 6909 protein-coding genes),
“cyan” with 1450 genes (1401), gray with 287 genes (257),
“midnight blue” with 3490 genes (3388), and salmon with
80 genes (79). The modules in the figure are not continu-
ous, as it was not possible to accurately represent distan-
ces based on eigenvalues in a two-dimensional plot.
The smallest of the identified clusters, the salmon clus-
ter, exhibited high overlap with the ANOVA results and in-
cluded 14 out of the 48 differentially expressed genes
Figure 2. Gene expression changes evoked by L-DOPA in the frontal cortex of rats with unilateral lesions of the dopaminergic sys-
tem. A total of 48 genes exhibit altered transcript abundance after L-DOPA treatment in the frontal cortex of rats with unilateral 6-
OHDA lesions (two-way ANOVA, FDR, 0.05). Each column represents one sample (left or right frontal cortex), and rows correspond
to genes as indicated on the right. Colors represent normalized expression levels. Genes are ordered based on hierarchical cluster-
ing, and the dendrogram is presented on the left. Additionally, the colored stripe on the right shows the assignment of genes to
modules from the WGCNA. Genes belonging to the salmon module are highlighted in bold and marked with a #. For detailed data
on the differentially expressed genes, see Extended Data Figure 2-1. For detailed data on alternative transcript isoforms of the dif-
ferentially expressed genes, see Extended Data Figures 2-2, 2-3. Additionally, the results of overrepresentation analyses are pre-
sented in Extended Data Figures 2-4 (transcription factor-binding sites) and 2-5 (drug-induced expression signatures).
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(Fig. 2; Extended Data Figs. 2-1, 2-3A). Seventy-nine out
of 80 genes in this module were protein-coding genes
(one was a pseudogene), and the module included several
IEGs (e.g., Fos, Fosb, Junb, Egr1, Arc, and Npas4), a large
proportion of which were related to transcription processes
(Fig. 3B). Of the 14 overlapping genes, 13 were clustered in
the dendrogram in Figure 2. The proximity of these 13 genes
on the heatmap dendrogram is consistent with expectations
as clustering is based on an approach similar to that of the
identification of coexpressed modules. The overlap in re-
sults from the two analytical methods cross validates the ef-
fects on L-DOPA on transcripts associated with immediate
early gene expression, which was hemisphere independent
(no specific effect of the lesion on the ipsilateral side). The
other coexpression modules exhibited relatively low
overlap with the differentially expressed genes (Fig. 3A).
The midnight blue module contained 18 differentially ex-
pressed genes, 15 of which were upregulated and three
Figure 3. L-DOPA-regulated gene coexpression networks in the rat frontal cortex. A, Graphic representation of gene assignment of the
12,455 genes [with log2(FPKM1 1) values .1] to WGCNA modules. Each branch of the dendrogram and colored stripe represent one
gene, and the colors indicate assignment to a particular module named by color. The dynamic tree cut method detected 17 modules (the
upper block of colored stripes), which were further joined with the “merge dynamic” method at a threshold of 0.5 into five resulting mod-
ules (the lower block). The numbers below the blocks indicate the total number of genes in a module, and those in brackets represent
the number of genes in the module that overlap with the differentially expressed genes. The module eigengenes for each sample are
shown in Extended Data Figure 3-1. B, The salmon module included many immediate early genes and was enriched in GO terms related
to the process of transcription. Biological process GO terms are on the left, and molecular function terms are on the right. Gray lines con-
nect the terms with the corresponding genes. For full results of overrepresentation analyses of the salmon module, please refer to
Extended Data Figures 3-2 (transcription factor-binding sites), 3-3 (GO), and 3-4 (drug-induced expression signatures).
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of which were downregulated. Of these 15 genes, nine
genes (Slc2a1, Tspan17, Mtmr1, Cavin2, Grasp, Efnb1,
Fibin, Id1, and Ifngr1) were adjacent in the heatmap
(Fig. 2). Additionally, the remaining six upregulated
genes were clustered on the dendrogram (branches
containing Tmem198, Mchr1, Chrm2, and Cdc42ep4
and Rgs16 and Il6r individually). However, an overlap
of 18 among 3490 is very low. Even smaller overlaps
were observed in the case of the brown (nine genes
among 7148) and cyan (seven genes among 1450) mod-
ules. The gray module, a collection of genes that were not
allocated to any module of coexpressed genes, did not in-
clude any differentially expressed genes. Therefore, we
performed further analyses of gene promoters and annota-
tion enrichment on the salmon module to obtain a result
complementary to the set of differentially expressed
genes.
Cell-type specificity of gene expression
L-DOPA impacts cells of different types and subtypes
(Yanovsky et al., 2011; Gantz et al., 2015; Masukawa et
al., 2017; Sagot et al., 2018); therefore, we analyzed the
differentially expressed genes to assess their expression
frequency within particular cell subtypes. We used large-
scale single-cell RNA-Seq murine datasets from the Allen
Institute for Brain Science to identify cell types with previ-
ously confirmed transcription of the differentially ex-
pressed genes (Allen Institute for Brain Science, 2015;
Tasic et al., 2018). For each gene of interest, we queried
the fraction of cells of each type in which it had been
found to be present (the criterion in the original paper was
CPM 1). The reported cell classification was based on
the expression of marker genes and clustering of tran-
scriptomic profiles using WGCNA and principal compo-
nent analysis. The analysis results are summarized in
Figure 4. Analysis of cell-type specificity of the expression of genes differentially expressed in the rat frontal cortex after L-DOPA
treatment. The heatmap includes genes that passed the differential expression criterion and had mouse homologs. Each column re-
flects a cell subtype, based on the Allen Atlas classification, and rows correspond to genes. The color of the squares in the heatmap
indicates the fraction of the cells belonging to the subtype that was found to express a particular gene (legend shown in the bottom
left). Symbols above the heatmap mark broader cell categories: triangles, neurons; diamonds, glia; dots, cells associated with the
vascular system. The colored stripe on the right indicates the assignment of genes to modules from the WGCNA. Genes belonging
to the salmon module are highlighted in bold and marked with a #. Astro, astrocytes; CR, Cajal–Retzius cells; CT, corticothalamic
neurons; Endo, endothelial cells; IT, intratelencephalic neurons; L, cortical layer; NP, near-projecting neurons; Oligo, oligodendro-
cytes; Peri, pericytes; PT, pyramidal tract neurons; SMC, smooth muscle cells; VLMC, vascular leptomeningeal cells.
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the heatmap shown in Figure 4. The use of fractions per-
mits the assessment of the ubiquity of gene expression;
however, it is not necessarily indicative of high levels of
transcription. In general, the heatmap shows that the
differentially expressed transcripts vary greatly in the
ubiquity of their expression. The upper part clusters
transcripts present in most types of cells and essentially
all types of neurons. Ypel5 is an example of a differen-
tially regulated transcript that was highly ubiquitous
(fraction of cells. 0.33 across all the cell subtypes). A
group of differentially expressed transcripts was preva-
lent in glutamatergic and GABAergic neurons, i.e.,
Errfi1, Fam43b, Mtmr1, Tmem198, and Tspan17. Genes
with relatively specific expression restricted to particular
subpopulations of GABAergic neurons (i.e., parvalbumin
or serpin F positive) included Hbegf and Rgs16, whereas
Rnf39 expression was detected mainly in glutamatergic
neurons. None of the differentially expressed genes
were specifically expressed by a single type of neuron.
The most specific expression was observed for Cebpa
and Klf4, which appeared restricted to macrophages
and endothelial cells, respectively. Some transcripts,
such as Mmp9 and Tnfrsf11b, were detected in less
than one-third of cells in all subtypes. To indirectly con-
firm cell-type specificity we also examined the expres-
sion of specific gene isoforms. In the cases of Sgk1-204
and Sgk1-201, it was previously reported that induction
of the former is specific to neurons, whereas the latter is
enriched in both neurons and astrocytes (Slezak et al.,
2013).
Gene promoter and annotation analyses
Next, we compared the lists of differentially expressed
genes and those included in the salmon module with
available gene annotation sources to explore shared reg-
ulatory factors, overlapping involvement in biological
processes or functions, and similarities in transcriptional
signature to reported effects of other drugs. The pro-
moter regions of genes with differential expression and
the salmon module for transcriptional factor binding were
analyzed using Seqinspector. The analysis identified eight
transcription factors with significantly increased binding in
the promoter regions of the differentially regulated
genes: early growth response protein 1 (EGR1), EGR2,
glucocorticoid receptor (GR), hypoxia-inducible factor
1-a (HIF1A), myoblast determination protein 1 (MYOD),
myogenin (MYOG), neuronal PAS domain protein 4
(NPAS4), and transcription factor 3 (TCF3; Extended
Data Fig. 2-4). In the case of the salmon module
genes, the analysis identified seven transcription fac-
tors, namely, MYOG, GR, NPAS4, and serum response
factor (SRF), CCAAT/enhancer-binding proteins b and
d (CEBPB and CEBPD, respectively), CREB-binding
protein (CBP; the complete list is presented in Extended
Data Fig. 3-2). The results are consistent with previous
analyses demonstrating that EGR1, EGR2, NPAS4 and
SRF are involved in the activation of the expression of
IEGs (Herdegen and Leah, 1998; Benito and Barco,
2015). Additionally, GR-dependent expression appears
in the acute response to treatment with most drugs,
including psychostimulants and drugs acting on dopa-
mine receptors (Piechota et al., 2012; Zygmunt et al.,
2019). The results of ontology analysis of the genes as-
signed to the salmon module with enrichR also appear
consistent with the idea of the activation of IEGs. A large
proportion of these genes act as transcription regulators,
and accordingly, 6 out of 8 enriched Gene Ontology (GO)
biological process terms as well as eight out of eight en-
riched GO molecular function terms were related to
transcriptional processes (Fig. 3B; for full results, see
Extended Data Fig. 3-3). One of the GO biological pro-
cess terms with significant overrepresentation was
“long-term memory” (GO:0007616), and the term was
assigned to Npas4, Arc, and Sgk1. On the other hand,
the 46 differentially expressed genes tested were not
significantly enriched in GO terms.
Next, we assessed overlaps between L-DOPA-regu-
lated genes and gene sets related to the response to
pharmacological treatment in the following databases:
the Drug Signatures Database (Yoo et al., 2015) and the
Gene Expression Omnibus (GEO) drug perturbations da-
tabase (full analysis results are shown in Extended Data
Fig. 2-5). A large number of significant overlaps were
identified, including expression patterns associated with
steroids (e.g., dexamethasone, estradiol, and corticoster-
one), antidiabetics (rosiglitazone and insulin), cytotoxic
and cytostatic agents (e.g., vemurafenib and actinomy-
cin D), vitamins (e.g., K3, retinoic acid, and ascorbic
acid), drugs targeting immune responses (e.g., lipopoly-
saccharide and etanercept), toxins (e.g., sodium arsen-
ite, vanadium pentoxide, and benzene), and drugs of
abuse (morphine, heroin, cocaine, and ethanol). The re-
sults of the analysis of the salmon module genes were
largely similar (Extended Data Fig. 3-4) with additional
significant results from the current release of the DrugMatrix
Database (United States Department of Health and Human
Services, 2010) that did not reveal any significant overlap
with the list of differentially expressed genes. Importantly,
these transcriptional signatures were reported in different
organisms and tissues, including the rat liver, a human
breast adenocarcinoma cell line and the murine striatum.
We noted that 41 of the L-DOPA-regulated genes and 65 of
the genes in the salmon module were represented in both of
the drug-related expression signature databases (i.e., Drug
Signatures Database and GEO database). This finding indi-
cates that a large subset of genes influenced by L-DOPA
are also activated by multiple other drugs, which may repre-
sent a nonspecific response. For instance, among the 319
significant overlaps between the sets from all the drug sig-
nature databases and the 46 differentially expressed genes
used in the analysis, Ddit4 appeared 155 times, and Hbegf
appeared in 114 cases (Extended Data Fig. 2-5). Similar
findings were noted for genes in the salmon module: Atf3
appeared in 724 out of 1166 total drug-regulated transcrip-
tion signatures, 594 signatures included Egr1, and 421 sig-
natures listed Dusp1 (Extended Data Fig. 3-4). Conversely,
34 of the differentially expressed genes were present in the
enrichment results of all the relevant drug-related data-
bases, and among genes in the salmon module, 19 were
present in the sets from the salmon significantly
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overrepresented databases. The 34 differentially expressed
genes in the drug sets were not associated with any of the
specific cell subtypes based on the analysis results shown
in Figure 4. These results may suggest that genes not in-
cluded in the overlaps with the transcriptional signatures of
other drugs are associated with molecular mechanisms spe-
cific to L-DOPA action. The four genes that were not present
in the transcriptional signatures included Grasp, Dipk2a,
Noct, and Cavin2. The latter three were not recognized by
the Allen Institute for Brain Science’s Cell Types Database
analytical tool. This leaves Grasp, which appears to be ex-
pressed predominantly in neurons as well as endothelial
cells (Fig. 4).
Finally, we performed a direct comparison of the results
of gene expression analysis with those of a recent com-
prehensive analysis of L-DOPA-induced transcription in
the rat striatum (Smith et al., 2016). A previous study iden-
tified 95 genes with decreased abundance in striatal tis-
sue in a unilateral 6-OHDA rat model of L-DOPA-induced
dyskinesia, of which 19 were included in the salmon mod-
ule (e.g., Arc, Atf3, Egr1, Egr2, and Nr4a1) and four in the
list of the differentially expressed genes (i.e., Klf4, Per1,
Cdc24ep4, and Nab2). However, it should be noted that
there are important methodological differences between
the cited study and this report, including the use of a dif-
ferent dose of L-DOPA (4mg/kg) in the case of the experi-
ments reported by Smith et al. (2016).
Discussion
We found that L-DOPA treatment in rats with unilateral
lesions of dopaminergic neurons largely induced bilateral
changes in gene expression in the frontal cortex. The dif-
ferentially expressed genes are functionally diverse and
include products engaged in the immediate early re-
sponse of the cell. Moreover, we also observed that in
the case of some genes, changes in expression exclu-
sively affected selected isoforms. Analysis of the cell-
type specificity of gene expression indicated that tran-
scription changes potentially occurred in both neuronal
and nonneuronal cell types. Finally, we found that with
the few exceptions, the differentially expressed genes
overlapped with genes regulated by other, functionally
unrelated drugs.
In general, 6-OHDA-induced lesioning of dopamine
neurons in rats is a widely used model of PD (Simola et
al., 2007). Several studies demonstrated differences in
IEG induction following the administration of a D1-like
receptor agonist and the contents of dopamine and its
metabolites between the lesioned and nonlesioned
hemispheres in animals with unilateral 6-OHDA lesions,
particularly in the striatum (Perese et al., 1989; Berke et
al., 1998; Walker et al., 2013), and at the level of monoa-
mine neurotransmitters in the substantia nigra, hippo-
campus and frontal cortex (Kaminska et al., 2017). We
found no genes with significant differences in expression
between the lesioned and intact sides of the frontal cor-
tex, with a single possible exception of an Mmp9 tran-
script. Analysis of alternative transcript isoforms of the
differentially expressed genes indicated an increased ex-
pression level of the longer Mmp9 splicing variant on the
contralateral (nonlesioned) side. Nevertheless, the al-
most universal bilateral changes in expression indicate
that either the unilateral lesion had no appreciable basal
effect on homeostasis in the frontal cortex, or the effects
on both sides were the same. We would argue that the
former is more likely based on the following reasons.
First, previous results confirmed depletion of dopamine
on the lesioned side of the frontal cortex of rats that
underwent the same treatment (Kaminska et al., 2017).
Second, the expression of markers of glial activation
(e.g., Gfap and Aif1) appeared normal and not indicative
of glial proliferation. This finding would imply a major dif-
ference from the observed sensitization of dopamine re-
ceptor D1 signaling observed in the dopamine-depleted
striatum (Berke et al., 1998). Although the bilateral ef-
fects in the frontal cortex may appear counterintuitive, it
was reported that a unilateral lesion of the nigrostriatal
pathway was associated with disrupted metabolic con-
nectivity between the ipsilateral auditory cortex and both
frontal cortices, whereas regional glucose metabolism was
significantly correlated between the lesioned striatum and
both motor cortices (Im et al., 2016). Similarly, in hemipar-
kinsonian rats, increases in the mRNA abundance of Arc in
the primary motor cortex following acute or chronic L-
DOPA treatment were bilateral despite a unilateral deple-
tion of TH-positive nerve fibers (Lindenbach et al., 2015).
The effects on Fos were lateralized (Lindenbach et al.,
2015); however, another report based on a similar lesion
model showed bilateral increases in Fos after L-DOPA
treatment (Monnot et al., 2017). Additionally, it should be
noted that D1 receptor sensitization in the lesioned stria-
tum was modulated by inputs from the contralateral pre-
frontal cortex (Herve et al., 1989). The transcriptomic
response to L-DOPA in the striatum and frontal cortex in
rodents with unilateral lesions of the nigrostriatal pathway
is thus spatially distinct and may follow tissue-specific reg-
ulatory mechanisms. Finally, we may not exclude the pos-
sibility that unilateral changes restricted to one of the
substructures (e.g., primary or secondary motor cortex) in-
cluded in the samples we analyzed, would be diluted and
thus missed in our analysis. We find this unlikely however
as the studies that assessed effects of dopamine receptor
agonists or L-DOPA on expression of Fos or other immedi-
ate-early genes exhibit broad activation of transcription
across all cortices (Berke et al., 1998; Monnot et al., 2017).
A comparison of the effects of L-DOPA on gene ex-
pression in the frontal cortex with results reported in
the striatum (Smith et al., 2016) reveals some overlap
in the differentially regulated genes identified. However, the
changes in transcription appear opposite in the case of
several putative IEGs. This finding could be consistent with
the notion that L-DOPA treatment in the dopamine-de-
pleted forebrain increases excitatory transmission from the
thalamus to cortical areas but reduces excitatory inputs
from the cortex to the striatum (De Deurwaerdère et al.,
2017). As previously indicated, the L-DOPA dose used in
the study by Smith and colleagues (2016) was considerably
lower (4mg/kg), which may also contribute to the observed
differences. Furthermore, we note that the previous proteo-
mic and transcriptomic analyses performed on samples
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taken postmortem from PD patients indicated neurodegen-
eration-related gene expression in the prefrontal cortex
(Dumitriu et al., 2016). Conversely, there was no indication
of frontal cortex degeneration after 6-OHDA lesioning in
rats (Simola et al., 2007), which may partially explain the
lack of differences in gene expression between hemi-
spheres that we observed. Finally, 6-OHDA lesioning
causes the loss of dopaminergic neurons within days of
treatment, whereas degeneration develops over years
before the onset of motor impairments in PD patients
(Morrish et al., 1998). Thus, although there is overlap to
some extent in gene expression changes reported here
and in previous studies on postmortem cortex samples,
e.g., Zfp189, Klhl21, Bcl6, and Dddit4 (Dumitriu et al.,
2016) or Nab2 and Sox2 (Dumitriu et al., 2012), a direct
comparison of 6-OHDA lesioning with postmortem anal-
yses does not appear valid. We consider this to be the
primary limitation of our study.
Our data showed that L-DOPA treatment had a robust
effect on gene expression in the frontal cortex. The effects
of L-DOPA appeared to involve two components: a gener-
al response and a drug-specific response. Both would be
of relevance in the context of the mechanisms through
which L-DOPA treatment affects cognitive functions re-
quiring cortical activity. We note extensive similarities be-
tween changes in gene expression induced by L-DOPA
treatment and those induced by other drugs, but we can-
not exclude the possibility that these changes are specific
to selected cell types. Thus, the specific aspect of drug-
induced gene expression could be the profile of the cells
affected rather than the exact list of affected transcripts.
Independently, as shown in the results, a single induced
transcript, Grasp (general receptor for phosphoinositides
1 associated scaffold protein, also known as Tamalin), ap-
peared to be specific to the effects of L-DOPA. Caution
should be taken in the case of such singular results, but
we note that the Grasp protein is involved in the trafficking
of metabotropic glutamate receptors (Kitano et al., 2002).
In addition, its increased abundance was reported in
postmortem CA1 hippocampal region samples from per-
sons diagnosed with schizophrenia (Matosin et al., 2015).
Grasp is upregulated in the ipsilateral striatum of rats with
6-OHDA unilateral lesions following chronic L-DOPA ex-
posure as well as in Flinders-resistant line rats that devel-
oped abnormal involuntary movements (a symptom of L-
DOPA-induced dyskinesia; Schintu et al., 2020). These ob-
servations support the notion that Grasp could be part of a
mechanism involved in the effects of L-DOPA on cognitive
functions; however, this notion remains a conjecture.
An additional point to consider is the cellular selectivity
of the response to L-DOPA. The method employed here
to determine the cell-type specificity of gene expression
does not provide direct information on cell-level gene ex-
pression changes; rather, we extrapolate data based on
the fraction of neuronal and nonneuronal cells that were
observed to express the genes of interest. The analysis
suggests a heterogeneous response to L-DOPA in the
frontal cortex involving different subtypes of neurons, glia,
macrophages and vascular cells. This finding is also con-
sistent with previous reports assessing the functions of
the differentially expressed genes. In the case of Sgk1,
which has extensively annotated isoforms, the change in
expression was selective for specific transcripts with the
canonical, astroglia-enriched and neuron-enriched variant
being upregulated and neuron-specific downregulated
(Arteaga et al., 2008; Slezak et al., 2013). Similarly,
Slc2a1, which encodes the GLUT1 glucose transport-
er, is considered a marker of the cells forming the
blood-brain barrier, whereas neurons predominantly
express GLUT3 (Xiuli et al., 2005). Taken together,
these results show that the observed changes in the
transcriptome may also affect nonneuronal cells.
A major caveat of analysis based on whole-tissue RNA-
Seq is that the changes we observe occur exclusively in
subsets of the cells indicated and speculatively may even
involve lesion-induced or L-DOPA-induced transcription
in cells that normally do not express the differentially
regulated genes.
Taken together, the results of gene expression analysis
in the context of previously reported data lead to two
conclusions. First, the effects of L-DOPA on the frontal
cortex are mainly not lateralized and thus substantially
differ from reported transcription changes in the stria-
tum. Second, the genes affected by L-DOPA overlap
with those reported in the cases of several other drugs;
hence, the key feature associated with the clinical effects
of L-DOPA is probably cell-type and transcript-isoform
specificity. We believe that extending the analysis of the
effects of L-DOPA on gene expression to achieve both
cell type and anatomic resolution could lead to the iden-
tification of patterns associated with antiparkinsonian
efficacy.
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